These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12691468)

  • 41. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 42. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication.
    Chou WW; Huang CF; Yeh ML; Tsai YS; Hsieh MY; Huang CI; Huang JF; Tsai PC; Hsi E; Juo SH; Tsai WL; Chuang WL; Yu ML; Dai CY
    J Mol Med (Berl); 2016 Mar; 94(3):311-20. PubMed ID: 26489607
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of direct antiviral agents in the management of hepatitis C.
    El Kassas M; Elbaz T; Hafez E; Esmat G
    Expert Opin Drug Saf; 2016 Dec; 15(12):1643-1652. PubMed ID: 27661100
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C virus genetic variability in patients undergoing antiviral therapy.
    Cristina J; del Pilar Moreno M; Moratorio G
    Virus Res; 2007 Aug; 127(2):185-94. PubMed ID: 17449128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hepatitis C virus-specific directly acting antiviral drugs.
    Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
    Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system.
    Chung RT; He W; Saquib A; Contreras AM; Xavier RJ; Chawla A; Wang TC; Schmidt EV
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9847-52. PubMed ID: 11493707
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus (HCV) replicons leading to drug development for hepatitis C cure.
    Zhao Q; Xia N
    Sci China Life Sci; 2016 Nov; 59(11):1198-1201. PubMed ID: 27785725
    [No Abstract]   [Full Text] [Related]  

  • 50. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemical genetics-based development of small molecules targeting hepatitis C virus.
    Jin G; Lee J; Lee K
    Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The molecular biology of hepatitis C virus].
    Koutsoudakis G; Forns X; Pérez-Del-Pulgar S
    Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New developments in the discovery of agents to treat hepatitis C.
    Rönn R; Sandström A
    Curr Top Med Chem; 2008; 8(7):533-62. PubMed ID: 18473882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effect of Stimforte in combination with Virazole on infection induced by hepatitis C virus in mice].
    Mal'dov DG; Deriabin PG; Il'ichev AV; Bel'kov AP; Isaeva EI
    Vopr Virusol; 2009; 54(3):42-5. PubMed ID: 19537096
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets.
    Hong Z; Standring DN; Baroudy B; Lau JY
    Acta Gastroenterol Belg; 2000; 63(2):210-2. PubMed ID: 10925468
    [No Abstract]   [Full Text] [Related]  

  • 59. Future therapy of hepatitis C.
    McHutchison JG; Patel K
    Hepatology; 2002 Nov; 36(5 Suppl 1):S245-52. PubMed ID: 12407600
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.